Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986620000012/alxn10k12312019.htm
July 2021
July 2021
May 2021
May 2021
April 2021
March 2021
February 2021
February 2021
January 2021
December 2020
• | 4Q19 total revenues of $1,384.3 million, a 23 percent increase over 4Q18 |
• | 4Q19 GAAP diluted EPS of $4.00; non-GAAP diluted EPS of $2.71 |
• | Received Japanese approval for SOLIRIS® (eculizumab) for neuromyelitis optica spectrum disorder (NMOSD) |
• | Established ULTOMIRIS® (ravulizumab) as market leader for PNH in U.S., Germany and Japan within first year of launch |
• | Continued strong SOLIRIS gMG and NMOSD launches, making neurology largest franchise in U.S. |
• | Expanded pipeline with 19 clinical-stage development programs planned for 2020 across 10 assets, including 2 Factor D inhibitors, following completion of Achillion acquisition |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986620000012/alxn10k12312019.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Alexion Pharmaceuticals, Inc..
Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0000899866-20-000012
Submitted to the SEC: Tue Feb 04 2020 6:30:53 AM EST
Accepted by the SEC: Tue Feb 04 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations